Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz' Hexal Wins Landmark German Case Over Desloratadine Switch

Executive Summary

Sandoz, through its Hexal subsidiary, has won an important case against the German Ministry of Health over a delayed prescription-to-OTC switch of desloratadine, which shows European Union Member States have got the authority to switch at a national level centrally authorized drugs.

You may also be interested in...



German Industry Wants To Simplify 'Complicated' Switch Process

The German Medicines Manufacturers´ Association

An Expert’s Guide To Switching In Germany, Part 1: Navigating The Reclassification Process

Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, talks exclusively to HBW Insight about prescription-to-OTC switching in Germany and the association’s efforts to improve this process.

UK CBD Industry Welcomes FSA Clarification On Novel Food Evidence Requirement

“With so little publicly available information on the safety of CBD we anticipate that directly relevant studies will be needed,” explains the UK Food Standards Agency, in response to confusion within the country's CBD industry. 

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel